Introduction: Botulinum neurotoxin A (BoNT-A) is a treatment option for neurogenic lower
urinary tract dysfunctions (NLUTD) and idiopathic overactive bladder (OAB) in adults …

Neurogenic lower urinary tract dysfunction (NLUTD), although not common in the general
population, can account for a significant portion of the practice of pediatric urologists. Unlike …

Purpose: Data are lacking on long-term outcomes of intradetrusor injections of botulinum
toxin A for neurogenic detrusor overactivity. The aim of this study was to assess the …

The objective was to evaluate the use of botulinum toxin A (BTX-A) injection in children with
medically refractory neurogenic bladder. A systematic review of the literature was conducted …

INTRODUCTION AND BACKGROUND neurogenic lower urinary tract dysfunction (nlUtd)
refers to abnormal function of the bladder, bladder neck, and/or sphincters associated with …

Introduction Neurogenic detrusor overactivity (NDO) results in involuntary detrusor
contractions during bladder filling or storage risking transmission of pressure to the upper …

Purpose Neurogenic lower urinary tract dysfunction (NLUTD) is common among children
with myelomeningocele (MMC). If NLUTD is not appropriately managed, recurrent urinary …

Purpose: Intradetrusor botulinum toxin is an established part of the treatment pathway for
pediatric patients with neurogenic bladder. We determined the urodynamic effect of single …

Botulinum neurotoxin A (BoNT/A), or Botox, is a popular option for overactive bladder (OAB)
and neurogenic bladder (NGB) with or without incontinence. This review aims to discuss the …

Purpose Deferring bladder augmentation (BA) may be desirable in a pediatric neurogenic
bladder (NGB) with worsening compliance, but prior studies have questioned whether …